CD274 and neoplasm: Although anti-CTLA 4 and anti-PD-1/PD-L1 antibodies have become the first-line treatment used against a wide variety of tumor types, due to the use of ICIs increasing T cell activity and eliminating the immune system from nature and “braking”, these drugs may be associated with immune-related adverse events (irAEs), especially when used in combination.